Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-164.44%
operating margin TTM
-131.12%
revenue TTM
107.08 Million
revenue per share TTM
2.29$
valuation ratios | |
|---|---|
| pe ratio | -7.02 |
| peg ratio | 1.60 |
| price to book ratio | -11.66 |
| price to sales ratio | 11.32 |
| enterprise value multiple | -8.79 |
| price fair value | -11.66 |
profitability ratios | |
|---|---|
| gross profit margin | 88.54% |
| operating profit margin | -131.12% |
| pretax profit margin | -160.04% |
| net profit margin | -164.44% |
| return on assets | -74.25% |
| return on equity | 503.46% |
| return on capital employed | -76.67% |
liquidity ratios | |
|---|---|
| current ratio | 4.14 |
| quick ratio | 3.99 |
| cash ratio | 1.95 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 240.81 |
| operating cycle | 316.91 |
| days of payables outstanding | 458.24 |
| cash conversion cycle | -141.33 |
| receivables turnover | 4.80 |
| payables turnover | 0.80 |
| inventory turnover | 1.52 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.60 |
| debt equity ratio | -1.35 |
| long term debt to capitalization | 3.87 |
| total debt to capitalization | 3.87 |
| interest coverage | -5.14 |
| cash flow to debt ratio | -0.98 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.59 |
| cash per share | 3.29 |
| operating cash flow per share | -2.58 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.98 |
| short term coverage ratios | -79.54 |
| capital expenditure coverage ratio | -310.94 |
Frequently Asked Questions
When was the last time UroGen Pharma Ltd. (NASDAQ:URGN) reported earnings?
UroGen Pharma Ltd. (URGN) published its most recent earnings results on 06-11-2025.
What is UroGen Pharma Ltd.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. UroGen Pharma Ltd. (NASDAQ:URGN)'s trailing twelve months ROE is 503.46%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. UroGen Pharma Ltd. (URGN) currently has a ROA of -74.25%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did URGN's net profit margin stand at?
URGN reported a profit margin of -164.44% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is URGN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.14 in the most recent quarter. The quick ratio stood at 3.99, with a Debt/Eq ratio of -1.35.